Abstract 25P
Background
With the advent of novel antibody-drug conjugate (ADC), an emerging subgroup of human epidermal growth factor receptor 2 (HER2)-low breast cancer has been recognized which may take advantage from the anti-tumor activity. We took advantage of Taiwan Cancer Registry (TCR) to evaluate the clinical presentations and prognostication for HER2-low breast cancer.
Methods
HER2-low breast cancers were defined operationally with HER2 immunohistochemistry (IHC) 1+ or 2+ with a negative fluorescence in situ hybridization (FISH) while HER2-zero defined with an IHC score 0. Breast cancer index cases (n=189465) from TCR between 2007 and 2017 were reduced to 133546 sides of breast cancer per subject. Clinical features such as IHC test, stage, grade and outcomes such as relapse-free and overall survival were compared between HER2-low and HER2-zero.
Results
The safety analysis group comprised 37195 HER2-negative breast cancers, including 14288 IHC 1+, 10486 FISH-negative, 8907 IHC 0 and 3323 IHC 2+/FISH-undetermined cases. Among HER2-negative breast cancers, the proportion of HER2-low and HER2-zero was 68.9% and 31.1%, respectively, after excluding HER2 ambiguity. Overall survival was 95.7% versus 95.9% for HER2-low and HER2-zero breast cancers, which was 94.1% and 94.7% for relapse-free survival. The distributions of pathological stages from 0 to IV were 6.7%, 41.5%, 38.5%, 13.1% and 0.3% for HER2-low and were 8.5%, 42.8%, 37.5%, 11% and 0.4% for HER2-zero breast cancers. Regarding estrogen receptor (ER) and progesterone receptor (PR) status, 87.6% and 80.9% of the HER2-low cases were ER+ and PR+ while 81.9% and 74.8% of the HER2-zero patients were ER+ and PR+. High or poorly differentiated grade was reported from 23.4% of HER2-low and 25.5% of HER2-zero breast cancers. The diagnosed age was 54 versus 54.3 between HER2-low and HER2-zero breast cancers (P=0.02).
Conclusions
HER2-low status is not a prognostic marker for Taiwanese breast cancers while a slightly younger age of disease onset, less than half diagnosed with stage 0 and I, more ER and PR positivity and fewer grade III disease were observed for HER2-low phenotype compared with HER2-zero counterpart. These trivial differences distinguished HER2-low from HER2-zero spectrum among Taiwanese HER2-negative breast cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
LMT.
Funding
Melissa Lee Cancer Foundation.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
194P - Real-world outcomes of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus chemotherapy as first-line treatment in advanced gastric (G) or gastroesophageal junction (GEJ) cancer with PD-L1 CPS≤5
Presenter: Qi Xu
Session: Poster Display
Resources:
Abstract
195P - Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis
Presenter: Quoc-Huy Trinh
Session: Poster Display
Resources:
Abstract
196P - Clinical significance of circulating CD8+ and CD4+ T cell proliferation in advanced gastric cancer receiving first-line chemotherapy
Presenter: In-Ho Kim
Session: Poster Display
Resources:
Abstract
197P - Treatment patterns and clinical outcomes of patients with unresectable advanced or metastatic (UAM) gastric/gastroesophageal junction adenocarcinoma (GA/GEJA) in China: A multicenter real-world study
Presenter: Yanqiao Zhang
Session: Poster Display
Resources:
Abstract
198P - Effectiveness of lenvatinib in patients with unresectable hepatocellular carcinoma: A multicenter observational study in Japan
Presenter: Namiki Izumi
Session: Poster Display
Resources:
Abstract
199P - Efficacy of endostar in combination with concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of esophagus: A randomized, open-label, phase II trial
Presenter: Yuexiao Qi
Session: Poster Display
Resources:
Abstract
200P - Prognosis of patients with hepatocellular carcinoma treated with transarterial chemoembolization: Development and validation of the ALFP score
Presenter: Baocuo Gong
Session: Poster Display
Resources:
Abstract
201P - A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma
Presenter: Zhenggang Ren
Session: Poster Display
Resources:
Abstract
202P - Comparison of liver injury after transcatheter arterial chemoembolization and hepatic arterial infusion chemotherapy for intermediate and advanced hepatocellular carcinoma
Presenter: Yongru Chen
Session: Poster Display
Resources:
Abstract
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract